Best of ASCO 2024 - 07/16/24 - Lung Cancer Living Room™

In this episode of Lung Cancer Living Room™, Danielle Hicks, Chief Patient Officer at GO2 for Lung Cancer, hosts Dr. Roy Herbst from the Yale Cancer Center to discuss the exciting news from ASCO 2024, the American Society for Clinical Oncology's annual meeting. Dr. Herbst highlights key findings and advancements in lung cancer research presented during the plenary sessions at ASCO, which included three major lung cancer studies.

The first of the plenary sessions discussed the comparative effectiveness of early palliative care delivered via telehealth versus in-person visits, emphasizing the importance of supportive care in improving patient outcomes. He notes that telehealth can be a viable option for providing palliative care, especially for patients in rural areas or with limited access to healthcare facilities.

The second study highlighted the use of targeted therapy after chemoradiation for metastatic lung cancer, specifically for patients with EGFR mutations. Dr. Herbst explains the significant benefits of using targeted therapies like osimertinib in combination with other treatments, which can lead to better progression-free survival rates.

The third plenary session focused on the addition of immunotherapy to the standard care for limited-stage small cell lung cancer. Dr. Herbst shares the promising results of the ADRIATIC trial, which showed improved progression-free and overall survival rates for patients receiving immunotherapy as part of their treatment.

Throughout the discussion, Dr. Herbst emphasizes the importance of personalized medicine and the need for comprehensive profiling of tumors to guide treatment decisions. He also highlights the potential of new drug combinations and innovative therapies, such as antibody-drug conjugates, in advancing lung cancer care.

Dr. Herbst concludes by encouraging patients and caregivers to stay informed about the latest advancements and to consider participating in clinical trials, as they play a crucial role in driving progress and improving outcomes for lung cancer patients.